Last reviewed · How we verify
Drug: Hyperacute Lung Cancer Cell Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Drug: Hyperacute Lung Cancer Cell Vaccine (Drug: Hyperacute Lung Cancer Cell Vaccine) — NewLink Genetics Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Drug: Hyperacute Lung Cancer Cell Vaccine TARGET | Drug: Hyperacute Lung Cancer Cell Vaccine | NewLink Genetics Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Drug: Hyperacute Lung Cancer Cell Vaccine CI watch — RSS
- Drug: Hyperacute Lung Cancer Cell Vaccine CI watch — Atom
- Drug: Hyperacute Lung Cancer Cell Vaccine CI watch — JSON
- Drug: Hyperacute Lung Cancer Cell Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Drug: Hyperacute Lung Cancer Cell Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-hyperacute-lung-cancer-cell-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab